TTY Biopharm Co.,Ltd.,a major pharmaceutical maker in Taiwan,recently inaugurated a drug factory in Suzhou,Jiangsu Province of China,operated by TTY`s Chinese subsidiary TOT Biopharm Co.,Ltd.
At a cost of about US$100 million,the factory mainly produces anti-cancer drug injections,TTY said.In addition,the company`s other new factory producing anti-cancer injections has also kicked off pilot run,and is expected to begin volume shipments by the end of the year after passing related certifications.With the two new facilities,TTY is expected to become a leader in Greater China in supplying anti-cancer injection.
TTY established TOT in 2010 to focus on developing and producing anti-cancer drugs,including tablets and solution injections.The firm has passed related certifications to be part of the Pharmaceutical Inspection Cooperation Scheme(PIC/S).
TOT`s Suzhou factory is the company`s first-stage investment,and the firm is scheduled to complete third-stage factory construction in the next four years.
Currently,TTY is the top-20 maker of anti-cancer drugs in terms of production value.TTY won high international reputation for its taxol anti-cancer drug(with abstraction from Taxus brevifolia tree in 2011),and is stepping into the liposomes anti-drug field.Lin claimed that liposomes is a nano-grade drug delivery technology that contains drugs inside liposomes to extend treatment period and decrease side-effects.
R.J.Lin,TTY`s chairman,pointed out that his company`s pilot-run factory in Chungli,northern Taiwan plans annual capacity of 800,000 injections,and as many as one million by 2013.The U.S.Food and Drug Administration(FDA)is expected to carry out plant inspection by the end of this year,when the new factory will soon kick off mass production.
